Regulatory Approval

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for MASHRegulatory Approvals

20 Jun 2025

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for MASH

Madrigal Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinio...

Zemcelpro® Receives Positive CHMP Opinion for Blood Cancer TreatmentRegulatory Approvals

20 Jun 2025

Zemcelpro® Receives Positive CHMP Opinion for Blood Cancer Treatment

ExCellThera announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opin...

Dupixent Approved for Bullous PemphigoidRegulatory Approvals

20 Jun 2025

Dupixent Approved for Bullous Pemphigoid

The FDA has approved Dupixent (dupilumab) for treating adult patients with bullous pemphigoid (BP), a chronic, debilitating, and rare skin disease. T...

Neuspera Medical Receives FDA Approval for Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge IncontinenceRegulatory Approvals

18 Jun 2025

Neuspera Medical Receives FDA Approval for Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge Incontinence

Neuspera Medical announced FDA approval of its integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI). This sys...

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-101 in Myotonic Dystrophy Type 1Regulatory Approvals

18 Jun 2025

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-101 in Myotonic Dystrophy Type 1

Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-101 for treating myotonic dystrophy type 1 (DM1). This foll...

FDA Approval of Keytruda for Head and Neck Cancer Highlights Potential for CEL-SCI's Multikine in PD-L1 Negative PatientsRegulatory Approvals

18 Jun 2025

FDA Approval of Keytruda for Head and Neck Cancer Highlights Potential for CEL-SCI's Multikine in PD-L1 Negative Patients

The FDA's approval of Merck's Keytruda for PD-L1 positive head and neck squamous cell carcinoma (HNSCC) based on interim Phase 3 data, sets a preceden...

FDA Approves IND Application for Myrio's PHOX2B PC-CAR T Therapy for NeuroblastomaRegulatory Approvals

16 Jun 2025

FDA Approves IND Application for Myrio's PHOX2B PC-CAR T Therapy for Neuroblastoma

Myrio Therapeutics announced that the FDA approved its Investigational New Drug (IND) application for PHOX2B PC-CAR T, a chimeric antigen receptor (CA...

FDA Delays Sebetralstat NDA Decision Due to Resource ConstraintsRegulatory Approvals

16 Jun 2025

FDA Delays Sebetralstat NDA Decision Due to Resource Constraints

KalVista Pharmaceuticals announced that the FDA will not meet the June 17, 2025 PDUFA goal date for sebetralstat, an investigational oral on-demand tr...

Moderna's RSV Vaccine, mRESVIA, Receives FDA Approval for Expanded Use in Adults Aged 18-59Regulatory Approvals

13 Jun 2025

Moderna's RSV Vaccine, mRESVIA, Receives FDA Approval for Expanded Use in Adults Aged 18-59

Moderna announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), its respiratory syncytial virus (RSV) vaccine, fo...

Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic SuspensionRegulatory Approvals

13 Jun 2025

Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal Pharmaceuticals announced FDA approval of its prednisolone acetate ophthalmic suspension 1%, a generic version of Pred Forte. This sterile, top...

FDA Approves Phraxis' EndoForce™ Connector for Dialysis AccessRegulatory Approvals

23 May 2025

FDA Approves Phraxis' EndoForce™ Connector for Dialysis Access

Phraxis Inc. announced FDA approval of its EndoForce™ Connector for Endovascular Venous Anastomosis, a medical device designed to simplify the creatio...

FDA Approves Genentech's Susvimo for Diabetic RetinopathyRegulatory Approvals

23 May 2025

FDA Approves Genentech's Susvimo for Diabetic Retinopathy

Genentech announced FDA approval of Susvimo (ranibizumab injection) 100 mg/mL for treating diabetic retinopathy (DR). Susvimo, delivered via a Port D...

FDA Approves Nucala for COPD ExpansionRegulatory Approvals

23 May 2025

FDA Approves Nucala for COPD Expansion

The FDA approved GSK's Nucala (mepolizumab), an anti-IL-5 antibody, for the treatment of chronic obstructive pulmonary disease (COPD). This approval e...

FDA Approves Arcutis' ZORYVE Topical Foam for Plaque PsoriasisRegulatory Approvals

23 May 2025

FDA Approves Arcutis' ZORYVE Topical Foam for Plaque Psoriasis

Arcutis Biotherapeutics announced FDA approval of ZORYVE (roflumilast) topical foam 0.3% for treating plaque psoriasis in adults and adolescents (12+)...

ENHERTU® Receives Time-Limited Reimbursement in Canada for Gastric CancerRegulatory Approvals

23 May 2025

ENHERTU® Receives Time-Limited Reimbursement in Canada for Gastric Cancer

AstraZeneca and Daiichi Sankyo announced that Canada's Drug Agency (CDA) has issued a Time-Limited Reimbursement (TLR) recommendation for ENHERTU® (tr...

FDA Approves Roche's Susvimo for Diabetic RetinopathyRegulatory Approvals

23 May 2025

FDA Approves Roche's Susvimo for Diabetic Retinopathy

The US Food and Drug Administration (FDA) has approved Roche's Susvimo (ranibizumab injection) 100 mg/mL for treating diabetic retinopathy (DR). Susv...

Saptalis Pharmaceuticals Launches LIKMEZ®, First FDA-Approved Ready-to-Use Metronidazole Oral SuspensionRegulatory Approvals

21 May 2025

Saptalis Pharmaceuticals Launches LIKMEZ®, First FDA-Approved Ready-to-Use Metronidazole Oral Suspension

Saptalis Pharmaceuticals announced the launch of LIKMEZ® (metronidazole) oral suspension, the first and only US FDA-approved ready-to-use oral liquid ...

QurAlis Licenses Novel Mechanism for Fragile X Syndrome TreatmentRegulatory Approvals

15 May 2025

QurAlis Licenses Novel Mechanism for Fragile X Syndrome Treatment

QurAlis Corporation announced an exclusive license agreement with UMass Chan Medical School for a novel RNA-targeted mechanism to treat Fragile X synd...

Cingulate's CTx-1301 for ADHD: FDA Alignment on NDA FilingRegulatory Approvals

15 May 2025

Cingulate's CTx-1301 for ADHD: FDA Alignment on NDA Filing

Cingulate Inc. announced that it received positive feedback from the FDA regarding its pre-New Drug Application (NDA) meeting for CTx-1301, a novel on...

Terumo Neuro Launches SOFIA™ 88 Neurovascular Support Catheter in the USRegulatory Approvals

14 May 2025

Terumo Neuro Launches SOFIA™ 88 Neurovascular Support Catheter in the US

Terumo Neuro announced the US commercial availability of the SOFIA™ 88 Neurovascular Support Catheter. This large-bore catheter is designed for relia...

Soleno Therapeutics Presents VYKAT™ XR Data at ISPOR 2025 for Prader-Willi SyndromeRegulatory Approvals

14 May 2025

Soleno Therapeutics Presents VYKAT™ XR Data at ISPOR 2025 for Prader-Willi Syndrome

Soleno Therapeutics announced presentations at the ISPOR 2025 meeting featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets for the...

Median Technologies Submits 510(k) Application for eyonis® LCS Lung Cancer Screening SaMDRegulatory Approvals

14 May 2025

Median Technologies Submits 510(k) Application for eyonis® LCS Lung Cancer Screening SaMD

Median Technologies announced the submission of a 510(k) application to the FDA for eyonis® LCS, an AI-powered software as a medical device (SaMD) for...

FDA Clears United Imaging's uAngio® AVIVA Interventional X-Ray SystemRegulatory Approvals

13 May 2025

FDA Clears United Imaging's uAngio® AVIVA Interventional X-Ray System

United Imaging announced FDA clearance for its uAngio® AVIVA interventional X-ray system. This ceiling-mounted system features intelligent robotics, ...

FDA and CDC Recommend Pause in IXCHIQ® Use for Elderly IndividualsRegulatory Approvals

12 May 2025

FDA and CDC Recommend Pause in IXCHIQ® Use for Elderly Individuals

Valneva announced that the FDA and CDC recommend pausing the use of their chikungunya vaccine, IXCHIQ®, in elderly individuals due to reported serious...

InnoCare's Mesutoclax Receives Breakthrough Therapy Designation in ChinaRegulatory Approvals

12 May 2025

InnoCare's Mesutoclax Receives Breakthrough Therapy Designation in China

InnoCare Pharma announced that its BCL2 inhibitor, Mesutoclax (ICP-248), received Breakthrough Therapy Designation from China's NMPA for treating rela...

FDA Grants Orphan Drug Designation to JR-446 for Mucopolysaccharidosis Type IIIBRegulatory Approvals

08 May 2025

FDA Grants Orphan Drug Designation to JR-446 for Mucopolysaccharidosis Type IIIB

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to JR-446, a drug developed by MEDIPAL HOLDINGS CORPORATION and JCR Pharma...

Viridian Therapeutics' Veligrotug Receives FDA Breakthrough Therapy Designation for Thyroid Eye DiseaseRegulatory Approvals

08 May 2025

Viridian Therapeutics' Veligrotug Receives FDA Breakthrough Therapy Designation for Thyroid Eye Disease

Viridian Therapeutics announced that the FDA granted Breakthrough Therapy Designation to veligrotug, its lead drug candidate for treating Thyroid Eye ...

← PrevPage 6 of 6